Yellow Card Scheme
Yellow Card Scheme
The Yellow Card Scheme is a pharmacovigilance system in the United Kingdom that allows healthcare professionals and patients to report adverse drug reactions (ADRs) to the Medicines and Healthcare products Regulatory Agency (MHRA). The scheme, which was established in 1964, is a crucial component of the UK's system for monitoring the safety of medicines and vaccines after they have been licensed for use.
History[edit | edit source]
The Yellow Card Scheme was introduced by the Committee on Safety of Medicines (CSM) following the Thalidomide disaster in the early 1960s. The scheme was named after the yellow cards that healthcare professionals were originally asked to send to the CSM if they suspected a medicine had caused an adverse reaction.
Purpose[edit | edit source]
The primary purpose of the Yellow Card Scheme is to provide an early warning system for the identification of previously unrecognised adverse reactions to medicines. It also provides a mechanism for the ongoing collection of data on the benefits and risks of medicines, which can be used to support decisions about the licensing of new medicines and the continued licensing of existing medicines.
Operation[edit | edit source]
The Yellow Card Scheme operates through the voluntary reporting of ADRs by healthcare professionals and patients. Reports can be submitted online, by post, or by telephone. The MHRA then analyses the reports and, if necessary, takes action to protect public health. This can include updating the information provided with a medicine, restricting its use, or in rare cases, withdrawing it from the market.
Limitations[edit | edit source]
While the Yellow Card Scheme plays a vital role in pharmacovigilance, it has some limitations. These include under-reporting of ADRs, lack of information about the number of people taking a medicine (which makes it difficult to calculate the incidence of ADRs), and the fact that it can only identify potential associations between a medicine and an adverse reaction, not prove causality.
See also[edit | edit source]
- Pharmacovigilance
- Adverse drug reaction
- Medicines and Healthcare products Regulatory Agency
- Committee on Safety of Medicines
References[edit | edit source]
External links[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
